Innate and adaptive immunity in celiac disease
Innate and adaptive immunity in celiac disease
批准号:
10685629
负责人:
BANA JABRI
金额:
$54.73万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
未结题
起止时间:
2005-09-09 至 2025-08-31
关键词:
AdultAffectAntibodiesArchitectureAtrophicBiopsyCD4 Positive T LymphocytesCD8B1 geneCeliac DiseaseCell CompartmentationCellsClinicalClinical TrialsComplexCytotoxic T-LymphocytesDataDevelopmentDigestive System DisordersDiseaseEffector CellEpithelial CellsFlow CytometryFundingGenetic TranscriptionGlutenGluten-free dietGoalsGranulocyte-Macrophage Colony-Stimulating FactorHLA-DQ2HLA-DQ8 antigenHealthHeterogeneityHumanImmunityImmunologyIndividualInflammatoryInterferon Type IIInterleukin-15IntestinesKiller CellsKnowledgeLamina PropriaLicensingLymphocyteLymphocyte ActivationMHC Class I GenesMediatingMissionMolecularMorphologyMusNational Institute of Diabetes and Digestive and Kidney DiseasesNatural ImmunityOutcomePathogenesisPathogenicityPathway interactionsPatientsPhenotypePopulationPrevention strategyPrognostic MarkerProxyResearchResolutionRoleSYK geneSignal TransductionSphingosine-1-Phosphate ReceptorStressSubgroupT-LymphocyteTNF geneTissue Transglutaminase AntibodiesTissuesUp-RegulationVillous AtrophyVillusWorkadaptive immunitycell motilitychemokinecytokinecytotoxicdietaryhigh dimensionalityhigh riskhuman diseaseimmune modulating agentsimmunopathologyimprovedindividual patientinterestintestinal epitheliumintraepithelialknowledge basemigrationmouse modelnew therapeutic targetnovel therapeutic interventionnovel therapeuticspredictive markerpreventprogramsrecruitsingle cell technologysingle-cell RNA sequencingtranscriptome sequencingtreatment strategyγδ T cells
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
Celiac disease (CeD), a complex T cell-mediated enteropathy induced by dietary gluten in HLA-DQ2 or HLA-
DQ8 individuals, currently affects 1% of the global population. While CD4 T cells are required for the
development of villus atrophy (VA), the effector cells mediating intestinal epithelial cell destruction (IEC) are
intraepithelial cytotoxic lymphocytes (IE-CTLS). Currently, the only effective CeD treatment is a lifelong gluten-
free diet (GFD). However, 30-40% of adult CeD patients fail to restore a completely normal intestinal
morphology on a GFD, and complete avoidance of gluten can be challenging. During the last funding period,
we generated the first HLA and gluten-dependent mouse model of CeD (CeD-tg) that recapitulates the
intricacies of CeD pathogenesis. We will take advantage of the CeD-tg mouse model and our expertise in
human immunology, to (i) further dissect the mechanisms underlying tissue destruction, and (ii) profile the
clinical spectrum of CeD using high dimensional single cell technologies with the goal of identifying new
therapeutic avenues and biomarkers predicting tissue destruction. The central hypothesis emerging from our
studies is that IE-CTL integrate signals from CD4 T cells and IEC to become licensed killer cells and mediate
tissue destruction. Furthermore, while it is acknowledged that IEC play a role in IE-CTL activation, their role in
CeD pathogenesis and how they impact on IE-CTL activation has not been investigated. The proposed specific
aims are:1) Establish the role of epithelial cells in T cell-mediated CeD immunopathology using the CeD Tg
mouse model; 2) Establish the Impact of γδ and CD4 T cells, IFNγ, IL-15 on IE-CTL activation in CeD-tg mice;
and 3) Profile the heterogeneity of potential and active CeD. The goal is to provide a knowledge base that will
help identify appropriate treatment strategies to individual patients, and help predict which potential CeD
patients (patients who have develop inflammatory anti-gluten immunity but conserve a normal intestinal
architecture) are at high risk of developing VA. The studies proposed will have a significant positive impact on
human health because they will help define curative and preventive strategies that have the potential to
prevent tissue destruction in celiac disease.
期刊论文(9)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1016/j.coi.2013.02.004
发表时间:
2013-06
期刊:
Current opinion in immunology
影响因子:
7
作者:
[Anderson RP, Jabri B]
通讯作者:
Jabri B
DOI:
10.1371/journal.pone.0076292
发表时间:
2013
期刊:
PloS one
影响因子:
3.7
作者:
[Tang F, Sally B, Ciszewski C, Abadie V, Curran SA, Groh V, Fitzgerald O, Winchester RJ, Jabri B]
通讯作者:
Jabri B
DOI:
10.4049/jimmunol.1400556
发表时间:
2014-07-15
期刊:
Journal of immunology (Baltimore, Md. : 1950)
影响因子:
--
作者:
[Orbelyan GA, Tang F, Sally B, Solus J, Meresse B, Ciszewski C, Grenier JC, Barreiro LB, Lanier LL, Jabri B]
通讯作者:
Jabri B
DOI:
10.1016/j.coi.2011.08.006
发表时间:
2011-12
期刊:
Current opinion in immunology
影响因子:
7
作者:
[Sollid LM, Jabri B]
通讯作者:
Jabri B
DOI:
10.1371/journal.pone.0001861
发表时间:
2008-03-26
期刊:
PloS one
影响因子:
3.7
作者:
[Siegel M, Strnad P, Watts RE, Choi K, Jabri B, Omary MB, Khosla C]
通讯作者:
Khosla C
Localizing Pathogenically Relevant Transglutaminase 2 in Celiac Disease
-
批准号:10704104
-
项目类别:
-
资助金额:$35.13万
-
财政年份:2021
-
负责人:BANA JABRI
-
依托单位:
Localizing Pathogenically Relevant Transglutaminase 2 in Celiac Disease
-
批准号:10296119
-
项目类别:
-
资助金额:$36.4万
-
财政年份:2021
-
负责人:BANA JABRI
-
依托单位:
Localizing Pathogenically Relevant Transglutaminase 2 in Celiac Disease
-
批准号:10483182
-
项目类别:
-
资助金额:$35.13万
-
财政年份:2021
-
负责人:BANA JABRI
-
依托单位:
GATA4 as a window into the link between metabolism and immunity
-
批准号:8570897
-
项目类别:
-
资助金额:$19.52万
-
财政年份:2013
-
负责人:BANA JABRI
-
依托单位:
GATA4 as a window into the link between metabolism and immunity
-
批准号:8715690
-
项目类别:
-
资助金额:$23.8万
-
财政年份:2013
-
负责人:BANA JABRI
-
依托单位:
Innate and adaptive immunity in celiac disease
-
批准号:8727526
-
项目类别:
-
资助金额:$31.6万
-
财政年份:2005
-
负责人:BANA JABRI
-
依托单位:
Innate and adaptive immunity in celiac disease
-
批准号:8528559
-
项目类别:
-
资助金额:$30.5万
-
财政年份:2005
-
负责人:BANA JABRI
-
依托单位:
IEL and NKG2 Receptors in Celiac Disease
-
批准号:7120637
-
项目类别:
-
资助金额:$30.51万
-
财政年份:2005
-
负责人:BANA JABRI
-
依托单位:
IEL and NKG2 Receptors in Celiac Disease
-
批准号:7485761
-
项目类别:
-
资助金额:$29.34万
-
财政年份:2005
-
负责人:BANA JABRI
-
依托单位:
IEL and NKG2 Receptors in Celiac Disease
-
批准号:7677961
-
项目类别:
-
资助金额:$29.34万
-
财政年份:2005
-
负责人:BANA JABRI
-
依托单位:
Innate and adaptive immunity in celiac disease
-
批准号:8322027
-
项目类别:
-
资助金额:$31.6万
-
财政年份:2005
-
负责人:BANA JABRI
-
依托单位:
Innate and adaptive immunity in celiac disease
-
批准号:8113974
-
项目类别:
-
资助金额:$31.6万
-
财政年份:2005
-
负责人:BANA JABRI
-
依托单位:
Innate and adaptive immunity in celiac disease
-
批准号:10462571
-
项目类别:
-
资助金额:$54.73万
-
财政年份:2005
-
负责人:BANA JABRI
-
依托单位:
IEL and NKG2 Receptors in Celiac Disease
-
批准号:7277833
-
项目类别:
-
资助金额:$29.85万
-
财政年份:2005
-
负责人:BANA JABRI
-
依托单位:
IEL and NKG2 Receptors in Celiac Disease
-
批准号:6980366
-
项目类别:
-
资助金额:$30.81万
-
财政年份:2005
-
负责人:BANA JABRI
-
依托单位:
Innate and adaptive immunity in celiac disease
-
批准号:10231243
-
项目类别:
-
资助金额:$54.73万
-
财政年份:2005
-
负责人:BANA JABRI
-
依托单位:
Innate and adaptive immunity in celiac disease
-
批准号:8009223
-
项目类别:
-
资助金额:$38.46万
-
财政年份:2005
-
负责人:BANA JABRI
-
依托单位:
Role of transglutaminase 2 in celiac sprue
-
批准号:10176470
-
项目类别:
-
资助金额:$69.61万
-
财政年份:2003
-
负责人:BANA JABRI
-
依托单位:
Role of Transglutaminase 2 in Celiac Sprue
-
批准号:10657792
-
项目类别:
-
资助金额:$69.93万
-
财政年份:2003
-
负责人:BANA JABRI
-
依托单位:
Regulation of normal human IEL by NKG2D and IL-15
-
批准号:7447862
-
项目类别:
-
资助金额:$26.95万
-
财政年份:2001
-
负责人:BANA JABRI
-
依托单位:
海外基金